Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHANGE Study of real-world ozanimod effectiveness in steroid-dependent ulcerative colitis
jRCT1031250583Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ozanimod and azathioprine in autoimmune colitis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of patients achieving steroid-free symptomatic remission at Week 12. Started Dec 2025; status: recruiting.
02
Drugs
ozanimodazathioprine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT1031250583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250583.